2 assets in Undifferentiated Carcinoma Of Stomach

Therapeutic assets addressing Undifferentiated Carcinoma Of Stomach, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Undifferentiated Carcinoma Of Stomach	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Undifferentiated Carcinoma Of Stomach	National Cancer Institute (NCI)	P2	CCC (53)